



Press release, October 10, 2023

## **Bulletin from Extra General Meeting of Diamyd Medical AB**

An Extraordinary General Meeting of Diamyd Medical AB was held today. The EGM approved the Board of Directors' resolution of September 20, 2023, on new issues of shares and warrants in the form of units. Complete information and documents regarding the EGM's resolutions are available on the company's website, <https://www.diamyd.com>.

### **Summary of the decisions**

Rights issue of shares and warrants of series TO3A, TO3B, TO4A and TO4B. If fully subscribed, the Rights Issue will raise issue proceeds of approximately SEK 243 million before issue costs.

Existing shareholders of Class A shares in Diamyd Medical as of the record date on October 13, 2023, will be allotted one (1) unit right A per one (1) existing Class A share, of which three (3) such unit A entitles the holder to subscribe for one (1) Class A unit in the rights issue. In addition, existing shareholders of Class B shares in Diamyd Medical will be granted one (1) unit right for every one (1) existing Class B share as of the record date 2023, of which three (3) such unit rights B entitle the holder to subscribe for one (1) Class B unit in the rights issue.

A total of 852,074 A-units and 27,742,030 B-units will be issued. Each A-unit consists of one (1) A-share, one (1) warrant of series TO3A free of charge, whereby two (2) warrants of series TO3A entitle the holder to subscribe for one (1) new share of the corresponding share class in the company during the period September 2 – September 30, 2024 at a subscription price of SEK 11.00, and one (1) warrant of series TO4A free of charge, whereby two (2) warrants of series TO4A entitle the holder to subscribe for one (1) new share of the corresponding share class in the Company during the period March 3 – March 31, 2025 at a subscription price of SEK 16.00. Each B-unit consists of one (1) B-share, one (1) warrant of series TO3B free of charge, whereby two (2) warrants of series TO3B entitle the holder to subscribe for one (1) new share of the corresponding share series in the company during the period September 2 – September 30, 2024 at a subscription price of SEK 11.00, and one (1) warrant of series TO4B free of charge, whereby two (2) warrants of series TO4B entitle the holder to subscribe for one (1) new share of the corresponding share class in the company during the period March 3 – March 31, 2025 at a subscription price of SEK 16.00.

A maximum of 852,074 new Class A shares and 1,704,148 warrants entitling to subscription of 852,074 Class A shares will be issued and a maximum of 27,742,030 new Class B shares and 55,484,060 warrants entitling to subscription of 27,742,030 Class B shares will be issued.

The subscription price per A-unit and B-unit, respectively, has been set at SEK 8.50. The warrants are issued free of charge. Upon full subscription, Diamyd Medical will initially receive an amount of approximately SEK 243 million before transaction costs. Upon full exercise of all warrants within the framework of issued units, the company will receive an additional total of approximately SEK 386 million before issue costs.

### **About Diamyd Medical**

Diamyd Medical develops precision medicine therapies for Type 1 Diabetes. Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset Type 1 Diabetes in eight European countries and has started in the US. Significant results have previously been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company's European Phase IIb trial DIAGNODE-2, where Diamyd® was administered directly into a lymph node in children and young adults with recently diagnosed Type 1 Diabetes. A biomanufacturing facility is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the antigen-

specific immunotherapy Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB.

Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.

**For further information, please contact:**

Ulf Hannelius, President and CEO

Phone: +46 736 35 42 41

E-mail: [ulf.hannelius@diamyd.com](mailto:ulf.hannelius@diamyd.com)

**Diamyd Medical AB (publ)**

Box 7349, SE-103 90 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68

E-mail: [info@diamyd.com](mailto:info@diamyd.com) Reg. no.: 556242-3797 Website: <https://www.diamyd.com>

**Publication**

The information was submitted for publication, through the agency of the contact person set out above, at 10.45 CET on October 10, 2023.